Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis.

@article{Herbrecht2002VoriconazoleVA,
  title={Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis.},
  author={Raoul Herbrecht and David W. Denning and Thomas F. Patterson and John E. Bennett and Reginald E. Greene and J{\"o}rg W. Oestmann and Winfried V. Kern and Kieren A. Marr and Patricia Ribaud and Olivier Lortholary and Richard J. Sylvester and Robert H. Rubin and John R. Wingard and Paul Stark and Christine M. Durand and Denis Caillot and Eckhard Thiel and Pranatharthi H Chandrasekar and Michael R. Hodges and Haran T. Schlamm and Peter F. Troke and Ben E. de Pauw},
  journal={The New England journal of medicine},
  year={2002},
  volume={347 6},
  pages={
          408-15
        }
}
BACKGROUND Voriconazole is a broad-spectrum triazole that is active against aspergillus species. We conducted a randomized trial to compare voriconazole with amphotericin B for primary therapy of invasive aspergillosis. METHODS In this randomized, unblinded trial, patients received either intravenous voriconazole (two doses of 6 mg per kilogram of body weight on day 1, then 4 mg per kilogram twice daily for at least seven days) followed by 200 mg orally twice daily or intravenous amphotericin… 

Figures and Tables from this paper

Voriconazole: in the treatment of invasive aspergillosis.

Voriconazole was generally well tolerated and showed excellent in vitro activity against Aspergillus spp.

An economic evaluation of voriconazole versus amphotericin B for the treatment of invasive aspergillosis in Canada.

Voriconazole as primary treatment for IA increased the chances of successful treatment, improved survival and may represent a potential cost saving strategy in Canada.

Voriconazole for invasive aspergillosis in oncohematological patients: a single-center pediatric experience

Voriconazole appears to be an effective salvage treatment for invasive aspergillosis in pediatric patients, with good responses in patients who recover from neutropenia or are not relapsing.

Liposomal Nystatin in Patients with Invasive Aspergillosis Refractory to or Intolerant of Amphotericin B

It is concluded that liposomal nystatin can be effective for salvage therapy of invasive aspergillosis in patients refractory to or intolerant of amphotericin B.

Amphotericin B lipid complex in the management of invasive aspergillosis in immunocompromised patients.

  • P. ChandrasekarJ. Ito
  • Medicine, Biology
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2005
Analysis of this large database demonstrated the efficacy and safety of ABLC in the treatment of invasive aspergillosis and no antagonism was observed when therapy with ABLC followed therapy with itraconazole.

Strategy of following voriconazole versus amphotericin B therapy with other licensed antifungal therapy for primary treatment of invasive aspergillosis: impact of other therapies on outcome.

  • T. PattersonH. Boucher J. Bennett
  • Medicine, Biology
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2005
The limited efficacy of salvage antifungal therapy, including therapy with lipid formulations of amphotericin B, is highlighted, and the importance of effective initial therapy in invasive aspergillosis is demonstrated.

Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial).

  • O. CornelyJ. Maertens R. Herbrecht
  • Medicine, Biology
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2007
In highly immunocompromised patients, the effectiveness of 3 mg/kg of liposomal amphotericin B per day as first-line therapy for invasive aspergillosis is demonstrated, with a response rate of 50% and a 12-week survival rate of 72%.

Efficacy of caspofungin as salvage therapy for invasive aspergillosis compared to standard therapy in a historical cohort

  • J. HiemenzI. Raad T. Walsh
  • Medicine, Biology
    European Journal of Clinical Microbiology & Infectious Diseases
  • 2010
Although only tentative conclusions about relative efficacy can be drawn from retrospective comparisons, caspofungin appeared to be at least as efficacious as an amphotericin B formulation and/or itraconazole for the treatment of invasive aspergillosis in patients refractory to or intolerant of their initial antifungal therapy.
...

References

SHOWING 1-10 OF 14 REFERENCES

Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever.

Voriconazole is a suitable alternative to amphotericin B preparations for empirical antifungal therapy in patients with neutropenia and persistent fever in a randomized, international, multicenter trial.

Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis.

  • D. DenningP. Ribaud H. Lode
  • Medicine
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2002
Voriconazole is efficacious in treating acute IA and is proven and probable in 68 patients, and good responses were seen in 60% of those with pulmonary or tracheobronchial IA and 26% of allogeneic stem cell transplant recipients.

Amphotericin B colloidal dispersion vs. amphotericin B as therapy for invasive aspergillosis.

  • M. WhiteE. Anaissie R. Bowden
  • Medicine, Biology
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 1997
It is suggested that in the treatment of aspergillosis ABCD causes fewer nephrotoxic effects than amphotericin B and the efficacy of ABCD is at least comparable with that of amphoteric in B.

Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis.

  • J. WingardP. Kubilis J. Lister
  • Medicine, Biology
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 1999
The data indicate that elevated creatinine levels during amphotericin B treatment are associated with a substantial risk for hemodialysis and a higher mortality rate, but the risks vary in different patient groups.

Amphotericin B and its new formulations: pharmacologic characteristics, clinical efficacy, and tolerability

The new lipid formulations of amB are effective in various invasive fungal infections and exhibit reduced nephrotoxicity compared with conventional amB, and Liposomal amB (AmBisome) is the only truly liposomal formulation.

Invasive Aspergillosis Disease Spectrum, Treatment Practices, and Outcomes

It is confirmed that mortality from invasive aspergillosis in severely immunosuppressed patients remains high even with standard amphotericin B, and new approaches and new therapies are needed to improve the outcome.

An EORTC international multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis.

  • M. EllisD. Spence B. Vandercam
  • Medicine
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 1998
This is the first completed prospective randomized clinical efficacy trial of antifungals in the treatment of invasive aspergillosis (IA) and the first to compare the clinical efficacy of two dosages

Practice Guidelines for Diseases Caused by Aspergillus

The recommendations are distilled in this summary, but the reader is encouraged to review the more extensive discussions in subsequent sections, which show the strength of the recommendations and the quality of the evidence.

The contribution of fluconazole to the changing epidemiology of invasive candidal infections.

  • M. White
  • Medicine, Biology
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 1997
This study raises a concern that undetected nosocomial factors are contributing to occasional increases in C. krusei infections among oncology patients and suggests that fluconazole use alters the etiology of candidemia their 5-year period of study.

Mortality and costs of acute renal failure associated with amphotericin B therapy.

  • D. BatesL. Su R. Platt
  • Medicine
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2001
The increases in resource utilization that are found are large and the associated mortality is high when acute renal failure occurs following amphotericin B therapy, and the related total cost is high.